124 related articles for article (PubMed ID: 33908819)
41. Expression of the heparan sulfate 6-O-endosulfatases, Sulf1 and Sulf2, in the avian and mammalian inner ear suggests a role for sulfation during inner ear development.
Freeman SD; Keino-Masu K; Masu M; Ladher RK
Dev Dyn; 2015 Feb; 244(2):168-80. PubMed ID: 25370455
[TBL] [Abstract][Full Text] [Related]
42. SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus.
Hassing HC; Surendran RP; Derudas B; Verrijken A; Francque SM; Mooij HL; Bernelot Moens SJ; Hart LM; Nijpels G; Dekker JM; Williams KJ; Stroes ES; Van Gaal LF; Staels B; Nieuwdorp M; Dallinga-Thie GM
Obesity (Silver Spring); 2014 May; 22(5):1309-16. PubMed ID: 24339435
[TBL] [Abstract][Full Text] [Related]
43. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells.
Nawroth R; van Zante A; Cervantes S; McManus M; Hebrok M; Rosen SD
PLoS One; 2007 Apr; 2(4):e392. PubMed ID: 17460759
[TBL] [Abstract][Full Text] [Related]
44. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
[TBL] [Abstract][Full Text] [Related]
45. Measuring sulfatase expression and invasion in glioblastoma.
Wade A; Engler JR; Tran VM; Phillips JJ
Methods Mol Biol; 2015; 1229():507-16. PubMed ID: 25325976
[TBL] [Abstract][Full Text] [Related]
46. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study.
Lui NS; van Zante A; Rosen SD; Jablons DM; Lemjabbar-Alaoui H
BMJ Open; 2012; 2(6):. PubMed ID: 23180455
[TBL] [Abstract][Full Text] [Related]
47. Plasma
Wang K; Song X; Li X; Zhang Z; Xie L; Song X
Future Oncol; 2022 Mar; 18(7):821-832. PubMed ID: 34842456
[No Abstract] [Full Text] [Related]
48. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer.
Li W; Wang Y; Zhang Q; Tang L; Liu X; Dai Y; Xiao L; Huang S; Chen L; Guo Z; Lu J; Yuan K
PLoS One; 2015; 10(8):e0134220. PubMed ID: 26237047
[TBL] [Abstract][Full Text] [Related]
49. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
50. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer.
Xiang C; Jin S; Zhang J; Chen M; Xia Y; Shu Y; Guo R
Int J Biol Markers; 2018 Aug; 33(3):314-320. PubMed ID: 29896992
[TBL] [Abstract][Full Text] [Related]
51. Discovery and validation of extracellular vesicle-associated miRNAs as noninvasive detection biomarkers for early-stage non-small-cell lung cancer.
Zhong Y; Ding X; Bian Y; Wang J; Zhou W; Wang X; Li P; Shen Y; Wang JJ; Li J; Zhang C; Wang C
Mol Oncol; 2021 Sep; 15(9):2439-2452. PubMed ID: 33340250
[TBL] [Abstract][Full Text] [Related]
52. Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.
Wang L; Xie L; Wang J; Shen J; Liu B
BMC Gastroenterol; 2013 Dec; 13():173. PubMed ID: 24359226
[TBL] [Abstract][Full Text] [Related]
53. Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer.
Liu WR; Zhang B; Chen C; Li Y; Ye X; Tang DJ; Zhang JC; Ma J; Zhou YL; Fan XJ; Yue DS; Li CG; Zhang H; Ma YC; Huo YS; Zhang ZF; He SY; Wang CL
Thorac Cancer; 2020 Nov; 11(11):3234-3242. PubMed ID: 32989915
[TBL] [Abstract][Full Text] [Related]
54. Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.
Guo J; Gao Y; Gong Z; Dong P; Mao Y; Li F; Rong J; Zhang J; Zhou Y; Feng H; Guo H; Gu L; An M; Wen K; Zhang J
Biomed Res Int; 2021; 2021():9623571. PubMed ID: 34712737
[TBL] [Abstract][Full Text] [Related]
55. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
56. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
57. SULF1/SULF2 reactivation during liver damage and tumour growth.
Graham K; Murphy JI; Dhoot GK
Histochem Cell Biol; 2016 Jul; 146(1):85-97. PubMed ID: 27013228
[TBL] [Abstract][Full Text] [Related]
58. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
59. A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.
Guo J; Wang X; Wang Y; Wang L; Hua S
Lung Cancer; 2019 Sep; 135():47-55. PubMed ID: 31447002
[TBL] [Abstract][Full Text] [Related]
60. Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients.
Noreldeen HAA; Du L; Li W; Liu X; Wang Y; Xu G
J Pharm Biomed Anal; 2020 Jun; 185():113220. PubMed ID: 32145537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
